Which thrombolytic drug is known to cause a higher incidence of allergic reactions?

Streptokinase is recognized for having a higher incidence of allergic reactions compared to the other thrombolytic drugs. This occurs because streptokinase is derived from streptococci bacteria, which can trigger immune responses in some individuals, leading to allergic reactions.

In contrast, alteplase, reteplase, and tissue plasminogen activator (tPA) are engineered to have fewer immunogenic properties, which typically results in a lower likelihood of inducing allergic responses. While all medicinal treatments can potentially lead to adverse effects, streptokinase's unique characteristics and patient reactions make it more prone to causing allergies than the others mentioned. Thus, the understanding of these differences is crucial in clinical settings when deciding on thrombolytic therapy for patients.